Daniel W Bowles

7PUBLICATIONS
90CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Molecular medicinePredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jun 26, 2024
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.

Jena D French, Bryan R Haugen, Francis P Worden

|Mar 13, 2024
Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.

Ilana M Braun, Kari Bohlke, Donald I Abrams

|Aug 29, 2023
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.

Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar

|Mar 02, 2023
A molecular guide to systemic therapy in salivary gland carcinoma.

Alice N Weaver, Stephanie Lakritz, Divneet Mandair

Pageof 2